Registro Absorb Italiano (BVS-RAI): An investigators-owned and -directed, open, prospective registry of consecutive patients treated with the Absorb™ BVS: Study design

Cardiovascular Revascularization Medicine

Volumn 16, Issue 6, 2015, Pages 340-343

  Cortese, Bernardo ^a   Ielasi, Alfonso ^b   Varricchio, Attilio ^c   Tarantini, Giuseppe ^d   LaVecchia, Luigi ^e   Pisano, Francesco ^f   Facchin, Michela ^g   Gistri, Roberto ^h   D'Urbano, Maurizio ⁱ   Lucci, Valerio ^j   Loi, Bruno ^k   Tumminello, Gabriele ^l   Colombo, Alessandro ^m   Limbruno, Ugo ⁿ   Nicolino, Annamaria ^o   Calzolari, Diego ^p   Tognoni, Gianni ^q   Defilippi, Gianfranco ^l   Buccheri, Dario ^a   Tespili, Maurizio ^b   Corrado, Donatella ^q   Steffenino, Giuseppe ^r   more..

^a FATEBENEFRATELLI HOSPITAL   (Italy)

^b BOLOGNINI HOSPITAL   (Italy)

^c MONALDI HOSPITAL   (Italy)

^d UNIVERSITY HOSPITAL OF PADOVA   (Italy)

^e Azienda Ospedaliera S Bortolo   (Italy)

^f Ospedale Regionale   (Italy)

^g Ospedale di Este (PD)   (Italy)

^h SAPIENZA UNIVERSITY OF ROME   (Italy)

ⁱ Ospedale di Magenta   (Italy)

^j Ospedale Civile di Avezzano   (Italy)

^k BROTZU HOSPITAL   (Italy)

^l Ospedale Cardinal Massaia   (Italy)

^m UNIVERSITY OF MILAN   (Italy)

ⁿ MISERICORDIA HOSPITAL   (Italy)

^o SANTA CORONA HOSPITAL   (Italy)

^p CA FONCELLO HOSPITAL   (Italy)

^q MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^r S CROCE E CARLE HOSPITAL   (Italy)

more..

Author keywords

BVS; Coronary artery disease; Long follow up; Prospective registry

Indexed keywords

EVEROLIMUS; IMMUNOSUPPRESSIVE AGENT;

ADULT; AGED; ARTICLE; BIORESORBABLE SCAFFOLD; CARDIOVASCULAR DISEASE; DEVICE SAFETY; FOLLOW UP; HUMAN; IMPLANT REGISTRY; ITALY; METHODOLOGY; MULTICENTER STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; STUDY DESIGN; BIODEGRADABLE IMPLANT; CORONARY STENOSIS; DRUG ELUTING STENT; PROSTHESIS DESIGN; REGISTER; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME;

ABSORBABLE IMPLANTS; AGED; CORONARY STENOSIS; DRUG-ELUTING STENTS; EVEROLIMUS; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; ITALY; PROSPECTIVE STUDIES; PROSTHESIS DESIGN; REGISTRIES; TREATMENT OUTCOME;

EID: 84941874303     PISSN: 15538389     EISSN: 18780938     Source Type: Journal    
DOI: 10.1016/j.carrev.2015.05.010     Document Type: Article

References (18)

1. Onuma Y., Dudek D., Thuesen L., Webster M., Nieman K., Garcia-Garcia H.M., et al. Five-year clinical and functional multislice computed tomography angiographic results after coronary implantation of the fully resorbable polymeric everolimus-eluting scaffold in patients with de novo coronary artery disease: the ABSORB cohort A trial. JACC Cardiovasc Interv 2013, 6:999-1009.
2. Serruys P.W., Onuma Y., Dudek D., Smits P.C., Koolen J., Chevalier B., et al. Evaluation of the second generation of a bioresorbable everolimus-eluting vascular scaffold for the treatment of de novo coronary artery stenosis: 12-month clinical and imaging outcomes. J Am Coll Cardiol 2011, 58:1578-1588.
3. Abizaid A., Costa J.R., Bartorelli A.L., Whitbourn R., van Geuns R.J., Chevalier B., et al. The ABSORB EXTEND study: preliminary report of the twelve-month clinical outcomes in the first 512 patients enrolled. EuroIntervention 2015, 10:1396-1401.
4. Onuma Y., Serruys P.W., Perkins L.E.L., Okamura T., Gonzalo N., Garcia-Garcia H.M., et al. Intracoronary optical coherence tomography and histology at 1month and 2, 3, and 4years after implantation of everolimus-eluting bioresorbable vascular scaffolds in a porcine coronary artery model: an attempt to decipher the human optical coherence tomography images in the ABSORB trial. Circulation 2010, 122:2288-2300.
5. Bruining N., de Winter S., Roelandt J.R.T.C., Regar E., Heller I., van Domburg R.T., et al. Monitoring in vivo absorption of a drug-eluting bioabsorbable stent with intravascular ultrasound-derived parameters a feasibility study. JACC Cardiovasc Interv 2010, 3:449-456.
6. Serruys P.W., Chevalier B., Dudek D., Cequier A., Carrié D., Iñiguez A., et al. A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial. Lancet 2015, 385:43-54.
7. NICE interventional procedure guidance http://www.nice.org.uk/guidance/ipg492.
8. Commissione Regionale Emilia-Romagna Dispositivi Medici, Report Novembre 2013 Su Scaffold Vascolare Bioriassorbibile http://www.saluter.it/documentazione/rapporti/scaffold_novembre_2013.pdf/view.
9. Tamburino C., Latib A., van Geuns R.J., Sabaté M., Mehilli J., Gori T., et al. Contemporary practice and technical aspects in coronary intervention with bioresorbable scaffolds: a European perspective. EuroIntervention 2015, 11:45-52.
10. Authors/Task Force Members, Windecker S., Kolh P., Alfonso F., Collet J.-P., Cremer J., et al. Authors/Task Force Members: 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 2014, 35:2541-2619.
11. Cutlip D.E., Windecker S., Mehran R., Boam A., Cohen D.J., van Es G.-A., et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 2007, 2344-2351.
12. Capodanno D., Gori T., Nef H., Latib A., Mehilli J., Lesiak M., et al. Percutaneous coronary intervention with everolimus-eluting bioresorbable vascular scaffolds in routine clinical practice: early and midterm outcomes from the European multicentre GHOST-EU registry. EuroIntervention 2015, 10:1144-1153.
13. Kraak R.P., Hassell M.E.C.J., Grundeken M.J., Koch K.T., Henriques J.P.S., Piek J.J., et al. Initial experience and clinical evaluation of the Absorb bioresorbable vascular scaffold (BVS) in real-world practice: the AMC Single Centre Real World PCI Registry. EuroIntervention 2015, 10:1160-1168.
14. Wöhrle J., Naber C., Schmitz T., Schwencke C., Frey N., Butter C., et al. Beyond the early stages: insights from the ASSURE registry on bioresorbable vascular scaffolds. EuroIntervention 2014 Dec 16, [Epub ahead of print]. 10.4244/EIJY14M12_10.
15. Testa L., Biondi-Zoccai G., Tomai F., Ribichini F., Indolfi C., Tamburino C., et al. Italian Diffuse/Multivessel Disease ABSORB Prospective Registry (IT-DISAPPEARS). Study design and rationale. J Cardiovasc Med (Hagerstown) 2015, 16:253-258.
16. Cortese B., Orrego P.S., Sebik R., Sesana M., Pisano F., Zavalloni D., et al. Biovascular scaffolding of distal left main trunk: experience and follow up from the multicenter prospective RAI registry (Registro Italiano Absorb). Int J Cardiol 2014, 177:497-499.
17. Ielasi A., Cortese B., Varricchio A., Tespili M., Sesana M., Pisano F., et al. Immediate and midterm outcomes following primary PCI with bioresorbable vascular scaffold implantation in patients with ST-segment myocardial infarction: insights from the multicentre "Registro ABSORB Italiano" (RAI registry). EuroIntervention 2014 Oct 30, [Epub ahead of print]. 10.4244/EIJY14M10_11.
18. Everaert B., Felix C., Koolen J., Den Heijer P., Henriques J., Wykrzykowska J., et al. Appropriate use of bioresorbable vascular scaffolds in percutaneous coronary interventions: a recommendation from experienced users. Neth Heart J 2015, 23:161-165.